These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 9669632)
1. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. Noor N; Small PK; Loudon MA; Hau C; Campbell FC Scand J Gastroenterol; 1998 Jun; 33(6):605-11. PubMed ID: 9669632 [TBL] [Abstract][Full Text] [Related]
2. Effects of oral cisapride on small bowel motility in irritable bowel syndrome. Evans PR; Bak YT; Kellow JE Aliment Pharmacol Ther; 1997 Oct; 11(5):837-44. PubMed ID: 9354190 [TBL] [Abstract][Full Text] [Related]
3. Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Small PK; Loudon MA; Hau CM; Noor N; Campbell FC Scand J Gastroenterol; 1997 Jan; 32(1):39-47. PubMed ID: 9018765 [TBL] [Abstract][Full Text] [Related]
4. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. Van Outryve M; Milo R; Toussaint J; Van Eeghem P J Clin Gastroenterol; 1991 Feb; 13(1):49-57. PubMed ID: 2007745 [TBL] [Abstract][Full Text] [Related]
5. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Farup PG; Hovdenak N; Wetterhus S; Lange OJ; Hovde O; Trondstad R Scand J Gastroenterol; 1998 Feb; 33(2):128-31. PubMed ID: 9517521 [TBL] [Abstract][Full Text] [Related]
7. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Schütze K; Brandstätter G; Dragosics B; Judmaier G; Hentschel E Aliment Pharmacol Ther; 1997 Apr; 11(2):387-94. PubMed ID: 9146780 [TBL] [Abstract][Full Text] [Related]
8. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Wagstaff AJ; Frampton JE; Croom KF Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744 [TBL] [Abstract][Full Text] [Related]
9. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Scarpignato C; Pelosini I Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210 [TBL] [Abstract][Full Text] [Related]
10. Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. Ziegenhagen DJ; Kruis W J Gastroenterol Hepatol; 2004 Jul; 19(7):744-9. PubMed ID: 15209619 [TBL] [Abstract][Full Text] [Related]
11. Mebeverine alters small bowel motility in irritable bowel syndrome. Evans PR; Bak YT; Kellow JE Aliment Pharmacol Ther; 1996 Oct; 10(5):787-93. PubMed ID: 8899088 [TBL] [Abstract][Full Text] [Related]
13. Dysmotility of the small intestine in irritable bowel syndrome. Kellow JE; Phillips SF; Miller LJ; Zinsmeister AR Gut; 1988 Sep; 29(9):1236-43. PubMed ID: 3197998 [TBL] [Abstract][Full Text] [Related]
14. Small bowel motility following major intra-abdominal surgery: the effects of opiates and rectal cisapride. Benson MJ; Roberts JP; Wingate DL; Rogers J; Deeks JJ; Castillo FD; Williams NS Gastroenterology; 1994 Apr; 106(4):924-36. PubMed ID: 8143997 [TBL] [Abstract][Full Text] [Related]
15. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. Inauen W; Emde C; Weber B; Armstrong D; Bettschen HU; Huber T; Scheurer U; Blum AL; Halter F; Merki HS Gut; 1993 Aug; 34(8):1025-31. PubMed ID: 8174947 [TBL] [Abstract][Full Text] [Related]
16. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807 [TBL] [Abstract][Full Text] [Related]
17. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051 [TBL] [Abstract][Full Text] [Related]
18. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506 [TBL] [Abstract][Full Text] [Related]
19. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769 [TBL] [Abstract][Full Text] [Related]
20. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]